fda warning letters glp-1 compounding september 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA takes aim at Hims

Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease

Dark spots are triggered by a combination of internal and external factors

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

540,541 Inclisiran has been approved for treating various cardiovascular conditions, including atherosclerotic cardiovascular disease (ASCVD), primary hypercholesterolemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia (HeFH)

Furthermore, research demonstrates that it attenuates oxidative stress markers and reduces blood-brain barrier breakdown following traumatic brain injury (3)

Beyond that, L-carnitine can reduce the availability of free fatty acids (FFAs), diminish the conversion of FFAs to TGs, and prevent excess TG accumulation in hepatocytes